|
1
|
Yeo CJ and Cameron JL: Prognostic factors
in ductal pancreatic cancer. Langenbecks Arch Surg. 383:129–133.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dunphy EP: Pancreatic cancer: a review and
update. Clin J Oncol Nurs. 12:735–741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O’Reilly MS, Boehm T, Shing Y, et al:
Endostatin: An endogenous inhibitor of angiogenesis and tumor
growth. Cell. 88:277–285. 1997.
|
|
4
|
Folkman J: Antiangiogenesis in cancer
therapy - endostatin and its mechanisms of action. Exp Cell Res.
312:594–607. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi HB, Huang YJ, Zhou H, et al: Nucleolin
is a receptor that mediates antiangiogenic and antitumor activity
of endostatin. Blood. 110:2899–2906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhuo W, Luo C, Wang X, Song X, Fu Y and
Luo Y: Endostatin inhibits tumour lymphangiogenesis and lymphatic
metastasis via cell surface nucleolin on lymphangiogenic
endothelial cells. J Pathol. 222:249–260. 2010. View Article : Google Scholar
|
|
7
|
Chen Y, Wang S, Lu X, Zhang H, Fu Y and
Luo Y: Cholesterol sequestration by nystatin enhances the uptake
and activity of endostatin in endothelium via regulating distinct
endocytic pathways. Blood. 117:6392–6403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kulke MH, Bergsland EK, Ryan DP, et al:
Phase II study of recombinant human endostatin in patients with
advanced neuroendocrine tumors. J Clin Oncol. 24:3555–3561. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang J, Sun Y, Liu Y, et al: Results of
randomized, multicenter, double-blind phase III trial of
rh-endostatin (YH-16) in treatment of advanced non-small cell lung
cancer patients. Chin J Lung Cancer. 8:283–290. 2005.(In
Chinese).
|
|
10
|
Roberts MJ, Bentley MD and Harris JM:
Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev.
54:459–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weis SM and Cheresh DA: Tumor
angiogenesis: molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang P, Chubb S, Hertel LW, Grindey GB
and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA
synthesis. Cancer Res. 51:6110–6117. 1991.
|
|
13
|
Plunkett W, Huang P, Xu YZ, Heinemann V,
Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of
action, and self-potentiation. Semin Oncol. 22:3–10.
1995.PubMed/NCBI
|
|
14
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
15
|
Rocha Lima CM and Centeno B: Update on
pancreatic cancer. Curr Opin Oncol. 14:424–430. 2002.
|
|
16
|
Guchelaar HJ, Richel DJ and van Knapen A:
Clinical, toxicological and pharmacological aspects of gemcitabine.
Cancer Treat Rev. 22:15–31. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprehensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
20
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar
|
|
21
|
Colucci G, Labianca R, Di Costanzo F, et
al: Randomized phase III trial of gemcitabine plus cisplatin
compared with single-agent gemcitabine as first-line treatment of
patients with advanced pancreatic cancer: the GIP-1 study. J Clin
Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Louvet C, Labianca R, Hammel P, et al;
GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin
compared with gemcitabine alone in locally advanced or metastatic
pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
J Clin Oncol. 23:3509–3516. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dugan E, Truax R, Meadows KL, et al: Phase
I dose escalation study of gemcitabine plus irinotecan in advanced
solid tumors. Anticancer Res. 29:5149–5153. 2009.PubMed/NCBI
|
|
24
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
25
|
Duffy A, Kortmansky J, Schwartz GK, et al:
A phase I study of erlotinib in combination with gemcitabine and
radiation in locally advanced, non-operable pancreatic
adenocarcinoma. Ann Oncol. 19:86–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ardavanis A, Kountourakis P, Karagiannis
A, Doufexis D, Tzovaras AA and Rigatos G: Biweekly gemcitabine
(GEM) in combination with erlotinib (ERL): an active and convenient
regimen for advanced pancreatic cancer. Anticancer Res.
29:5211–5217. 2009.PubMed/NCBI
|
|
27
|
Scheithauer W, Schull B, Ulrich-Pur H, et
al: Biweekly high-dose gemcitabine alone or in combination with
capecitabine in patients with metastatic pancreatic adenocarcinoma:
a randomized phase II trial. Ann Oncol. 14:97–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eder JP, Supko JG, Clark JW, et al: Phase
I clinical trial of recombinant human endostatin administered as a
short intravenous infusion repeated daily. J Clin Oncol.
20:3772–3784. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herbst RS, Hess KR, Tran HT, et al: Phase
I study of recombinant human endostatin in patients with advanced
solid tumors. J Clin Oncol. 20:3792–3803. 2002. View Article : Google Scholar : PubMed/NCBI
|
